DongKoo Bio & Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
March 20, 2023 at 08:07 am
Share
DongKoo Bio & Pharma Co., Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was KRW 2,861.96 million compared to KRW 2,946.62 million a year ago. Net income was KRW 6,613.93 million compared to KRW 9,326.59 million a year ago.
Basic earnings per share from continuing operations was KRW 238 compared to KRW 330 a year ago. Basic earnings per share was KRW 238 compared to KRW 330 a year ago.
Dongkoo Bio&Pharma Co.,Ltd. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The major products include antihistamines, topical steroids, therapeutic agents for prostatitis, treatments for benign prostatic hyperplasia, atherosclerotic agents, and antibiotics, among others. The Company is involved in contract manufacturing organization business. It manufactures and sells therapeutic for osteoporosis, antiviral agents, erectile dysfunction treatments, hepatic disease agents; painkillers; gum treatments. In addition, the Company is engaged in the manufacturing and sale of medical devices and cosmetics. The Company distributes its products within the domestic market and to overseas markets, including America and Europe.
DONGKOO BIO & PHARMA CO., LTD. 
